Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.

Cancer research - 15 Jun 2000

Wan Y, Bramson J, Pilon A, Zhu Q, Gauldie J

Abstract excerpt

Genetic immunization through ex vivo transduction of dendritic cells has been suggested as an effective approach to enhance antitumor immunity by activating both CD4+ and CD8+ T cells. Immunizing mice with dendritic cells transduced with an adenovirus expressing the human melanoma antigen glycoprotein 100 (DCAdhgp100) as a cancer vaccine, we demonstrated complete protective immunity and a potent CTL response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Autoimmunity
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD40 Ligand

Share to Interleukin-12

Share to Melanoma, Experimental

Share to Spleen

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 10866318

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.PMID 10866318Read ↗

Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.Semantic proximity Read ↗

Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.Semantic proximity Read ↗

Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.Semantic proximity Read ↗

Active immunization against cancer with dendritic cells: the near future.Semantic proximity Read ↗

New approaches to the development of adenoviral dendritic cell vaccines in melanoma.Semantic proximity Read ↗

Gene-modified dendritic cell vaccines for cancer.Semantic proximity Read ↗

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.Semantic proximity Read ↗

A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10.Semantic proximity Read ↗

MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.Semantic proximity Read ↗

Dendritic cell vaccines in melanoma: from promise to proof?Semantic proximity Read ↗

Overview of melanoma vaccines and promising approaches.Semantic proximity Read ↗

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.